# US 2016/0355498 A1 · Inhibitors of bruton's tyrosine kinase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355498 A1
- Document ID: US20160355498A1
- Status: Published application
- Kind: A1
- Application number: 15/173,182
- Filed: 2016-06-03
- Published: 2016-12-08
- Earliest claimed: 2013-12-05
- Assignees: Pharmacyclics, Inc.
- Applicants: Pharmacyclics LLC
- Inventors: Wei Chen; Zhaozhong J. Jia; William D. Thomas
- Web page: https://patentgrep.com/patent/US20160355498A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/497: containing further heterocyclic rings
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

## Claims

### Claim 1

A compound of Formula (IA) having the structure:
wherein:
ring A is substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, or substituted or unsubstituted C1-C12heteroaryl;
W is —C(R2)— or —N—;
X is —C(R2)— or —N—;
Y is optionally present and when present is —CH2O—, —OCH2—, —OCH2CH2O—, —O—, —N(R3)—, —C(O)—, —N(R3)C(O)—, —C(O)N(R3)—, —N(R3)C(O)N(R3)—, —S(O)—, —S(O)2—, —N(R3)S(O)2—, —S(O)2N(R3)—, —C(═NH)—, —C(═NH)N(R3)—, —C(═NH)N(R3)—, or substituted or unsubstituted C1-C4alkylene;
Z is optionally present and when present is substituted or unsubstituted C1-C3alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, or substituted or unsubstituted C1-C12heteroaryl;
G is
R1 is —R4, —CH2R4, —C(O)R9, —C(O)C(O)R9, —C(O)OR4, —C(O)N(R3)(R4), or —S(O)2R9;
R1′ is —C(O)R9′, —C(O)C(O)R9, —C(O)OR4, —C(O)N(R3)(R4), or —S(O)2R9;
each R2 is independently H, substituted or unsubstituted C1-C4alkyl, —CN, or halogen;
each R3 is independently is H, or substituted or unsubstituted C1-C4alkyl;
each R4 is independently H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, or substituted or unsubstituted C1-C12heteroaryl;
R5 is H, substituted or unsubstituted C1-C4alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, or substituted or unsubstituted C1-C12heteroaryl; or R1 and R5 together with the nitrogen atom to which they are attached are combined to form a substituted or unsubstituted C2-C9heterocycloalkyl ring;
each R6 is independently halogen, —CN, —OH, —NH2, substituted or unsubstituted C1-C4alkoxy, substituted or unsubstituted C1-C4alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C6heterocycloalkyl, or —N(R3)2; or R1 and R6 are combined to form a substituted or unsubstituted C2-C9heterocycloalkyl ring;
each R7 is independently halogen, —CN, —OH, —NH2, substituted or unsubstituted C1-C4alkoxy, substituted or unsubstituted C1-C4alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C6heterocycloalkyl, or —N(R3)2;
R9 is —R4, or
R10 is H, halogen, —CN, or -L1-L2;
R11 and R12 are independently H, halogen, —CN, or -L1-L2; or R11 and R12 taken together form a bond;
each L1 is optionally present and when present each L1 is independently substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, substituted or unsubstituted C1-C12heteroaryl, —C(═O)—, —O—, or —S—;
each L2 is independently H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, substituted or unsubstituted C1-C12heteroaryl or —N(R13)2;
each R13 is independently H, C1-C6alkyl, C3-C6cycloalkyl, C1-C6heteroalkyl, C2-C7 heterocycloalkyl, C6-C12aryl, or C1-C12heteroaryl;
n is 0-3;
p is 0-3; and
q is 0-3;
or a pharmaceutically acceptable solvate, pharmaceutically acceptable salt, or pharmaceutically acceptable prodrug thereof;
provided that
i) when W is N, and R1 is H, t-Boc, or —C(O)—CH═CH2; then X is other than C-Et or N; and
ii) when W is N, G is
then X is CH or N;
iii) when W is N, and X is CH; then R1′ is other than —C(O)Me, or t-Boc; and
iv) when n is 0; then each of p and q is independently 0, 1, or 2.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein the compound is of Formula (I) having the structure:
wherein:
ring A is substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, or substituted or unsubstituted C1-C12heteroaryl;
W is —C(R2)— or —N—;
X is —C(R2)— or —N—;
Y is optionally present and when present is —CH2O—, —OCH2—, —OCH2CH2O—, —O—, —N(R3)—, —C(O)—, —N(R3)C(O)—, —C(O)N(R3)—, —N(R3)C(O)N(R3)—, —S(O)—, —S(O)2—, —N(R3)S(O)2—, —S(O)2N(R3)—, —C(═NH)—, —C(═NH)N(R3)—, —C(═NH)N(R3)—, or substituted or unsubstituted C1-C4alkylene;
Z is optionally present and when present is substituted or unsubstituted C1-C3alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, or substituted or unsubstituted C1-C12heteroaryl;
G is
R1 is —R4, —CH2R4, —C(O)R9, —C(O)C(O)R9, —C(O)OR4, —C(O)N(R3)(R4), or —S(O)2R9;
each R2 is independently H, —CN, or halogen;
each R3 is independently is H, or substituted or unsubstituted C1-C4alkyl;
each R4 is independently H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, or substituted or unsubstituted C1-C12heteroaryl;
R5 is H, substituted or unsubstituted C1-C4alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, or substituted or unsubstituted C1-C12heteroaryl; or R1 and R5 together with the nitrogen atom to which they are attached are combined to form a substituted or unsubstituted C2-C9heterocycloalkyl ring;
each R6 is independently halogen, —CN, —OH, —NH2, substituted or unsubstituted C1-C4alkoxy, substituted or unsubstituted C1-C4alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C6heterocycloalkyl, or —N(R3)2; or R1 and R6 are combined to form a substituted or unsubstituted C2-C9heterocycloalkyl ring;
each R7 is independently halogen, —CN, —OH, —NH2, substituted or unsubstituted C1-C4alkoxy, substituted or unsubstituted C1-C4alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C6heterocycloalkyl, or —N(R3)2;
R9 is —R4, or
R10 is H, halogen, —CN, or -L1-L2;
R11 and R12 are independently H, halogen, —CN, or -L1-L2; or R11 and R12 taken together form a bond;
each L1 is optionally present and when present each L1 is independently substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, substituted or unsubstituted C1-C12heteroaryl, —C(═O)—, —O—, or —S—;
each L2 is independently H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, substituted or unsubstituted C1-C12heteroaryl or —N(R13)2;
each R13 is independently H, C1-C6alkyl, C3-C6cycloalkyl, C1-C6heteroalkyl, C2-C7 heterocycloalkyl, C6-C12aryl, or C1-C12heteroaryl;
p is 0-3; and
q is 0-3;
or a pharmaceutically acceptable solvate, pharmaceutically acceptable salt, or pharmaceutically acceptable prodrug thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein
G is

### Claim 4 (depends on 3)

The compound of claim 3, wherein
G is

### Claim 5 (depends on 1, 2)

The compound according to claim 1, wherein the compound is of Formula (IV) having the structure:
wherein A, W, X, Y, Z, R1, R5, and R6 are as in claim 2.

### Claim 6 (depends on 5)

The compound of claim 5, wherein R6 is Me.

### Claim 7 (depends on 5)

The compound of claim 5, wherein ring A is phenyl.

### Claim 8 (depends on 5)

The compound of claim 5, wherein Y is absent, —CH2O—, —OCH2—, —O—, —N(R3)—, —C(O)—, —N(R3)C(O)—, —C(O)N(R3)—, or substituted or unsubstituted C1-C4alkylene.

### Claim 9 (depends on 5)

The compound of claim 5, wherein Z is substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, or substituted or unsubstituted C1-C12heteroaryl.

### Claim 10 (depends on 5)

The compound of claim 5, wherein R1 is —C(O)R9.

### Claim 11 (depends on 10)

The compound of claim 10, wherein R9 is —R4, and R4 is substituted or unsubstituted C6-C12aryl, or substituted or unsubstituted C1-C12heteroaryl.

### Claim 12 (depends on 5)

The compound of claim 5, wherein ring A is substituted or unsubstituted C1-C12heteroaryl.

### Claim 13 (depends on 12)

The compound of claim 12, wherein ring A is pyridyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, or isoxazolyl.

### Claim 14 (depends on 5)

The compound of claim 5, wherein X is —C(H)—.

### Claim 15 (depends on 5)

The compound of claim 5, wherein X is —N—.

### Claim 16 (depends on 5)

The compound of claim 5, wherein W is —C(H)—.

### Claim 17 (depends on 5)

The compound of claim 5, wherein W is —N—.

### Claim 18 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, and a pharmaceutically acceptable excipient.

### Claim 19 (depends on 1)

A method for treating an autoimmune disease or condition comprising administering to a patient in need a therapeutically effective amount of a compound of claim 1.

### Claim 20 (depends on 19)

The method of claim 19, wherein the autoimmune disease is selected from rheumatoid arthritis or lupus.
